Evidence map›Paper›PMID 41803140›Full record

ArticleNature communications2026

Restoration of RBM22 overcomes the transcriptional and epigenetic barriers of cardiomyocyte proliferation for heart regeneration.

Xuewen Duan, Yong Tan, Yunkai Zhang, Bo Wang, Sheng Zhang, Tong Li, Xingguang Liu, Zhenzhen Zhan

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuewen Duan *Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yong Tan *State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yunkai Zhang *Naval Medical Center, Naval Medical University, Shanghai, China.ORCID http://orcid.org/0009-0007-4932-6270
Bo WangDepartment of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-9474-0274
Sheng ZhangShanghai Institute of Transplantation, Shanghai Engineering Research Centre of Transplantation and Immunology, Shanghai, China.
Tong LiState Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Xingguang LiuNational Key Laboratory of Immunity & Inflammation, Department of Pathogen Biology, Naval Medical University, Shanghai, China.ORCID http://orcid.org/0000-0002-1928-8847
Zhenzhen ZhanDepartment of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhanzz2022@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-4943-1659

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32400727National Natural Science Foundation of China (National Science Foundation of China) 82371825, 82572083National Natural Science Foundation of China (National Science Foundation of China) 82500323
6 · The paper itself

Abstract

Stimulating endogenous cardiomyocyte proliferation holds great therapeutic promise for cardiac repair, but how chromatin remodeling governs this process remains poorly understood. RNA-binding motif 22 (RBM22) participates in the regulation of various biological contexts, whereas its role in cardiac regeneration and repair is largely unknown. Here, we identify RBM22 as a pivotal regulator of cardiomyocyte proliferation. Cardiomyocyte-specific deletion of Rbm22 impairs neonatal heart regeneration and exacerbates post-infarction ventricular remodeling in adult mice. Mechanistically, RBM22 selectively binds to the proximal promoters of key cell cycle genes (Cdk4, Ccna2, and Ccne1), where it cooperates with chromatin remodeler SMARCA4 to enhance transcriptional accessibility. Furthermore, RBM22 is essential for the gene-specific recruitment of RNA Polymerase II to these gene loci to drive transcription. AAV9-mediated delivery of Rbm22 promotes cardiomyocyte proliferation in vivo following cardiac damage and increases the proliferation of human induced pluripotent stem cell-derived cardiomyocytes. Our findings establish RBM22 as a transcriptional and epigenetic regulator that overcomes cell-cycle barriers in cardiomyocytes, highlighting its therapeutic potential for cardiac injury.

Indexed as

Epigenesis, GeneticHeartMyocytes, CardiacRegenerationRNA-Binding ProteinsAnimalsCell ProliferationDNA HelicasesHumansMaleMiceMyocardial InfarctionNuclear ProteinsPromoter Regions, GeneticRNA Polymerase IITranscription FactorsDNA HelicasesNuclear ProteinsRNA-Binding ProteinsRNA Polymerase IISmarca4 protein, mouseTranscription Factors

Identifiers

PMID41803140
PMCPMC13100029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.